Company intelligence / Profile preview

UbiVac

Portland, Oregon, United Statesubivac.com ↗

Ownership: Private
Development stage: Phase 1

Overview

DPV-001 (lead product) has induced and/or boosted immune response in every patient evaluated to date (AACR 2024). Early data shows tripling or more of response rate in HNSCC patients receiving DPV-001 as part of combination immunotherapy.

Therapeutic areas: Oncology
Modalities: Therapeutic immune activatorsVaccinesCellular immunotherapies
Industry: Biotech

Drug pipeline

7 assets

DPV-001

6 more assets in the full pipeline.

Request access →

Partnerships

National Cancer Institute (supporting clinical trial)

Beyond the preview

Go deeper on UbiVac.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UbiVac.

Explore the full profile